Key terms

About MOR

MorphoSys AG is a biopharmaceutical company, which engages in the development and commercialization of cancer therapeutics. Its clinical programs focus on Pelabresib and Tulmimetostat. The company was founded by Andreas Pluckthun and Simon E. Moroney in July 1992 and is headquartered in Planegg, Germany.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest MOR news

Apr 12 11:57am ET MorphoSys AG Reports Major Norwegian Stake Apr 11 9:12am ET MorphoSys board recommends shareholders accept Novartis offer Apr 11 8:59am ET MorphoSys Management, Supervisory board recommend Novartis takeover Apr 09 10:57am ET MorphoSys AG Reports Major Shareholding Change Apr 08 10:57am ET MorphoSys AG’s Ownership Shift: Goldman Sachs Acquires Stake Apr 04 10:57am ET Barclays PLC Adjusts Stake in MorphoSys AG Apr 02 11:27am ET MorphoSys AG Announces Capital Increase Mar 27 1:57pm ET MorphoSys AG Reports Major Shareholding Changes Mar 26 11:57am ET MorphoSys AG Reports Major Shareholding Change Mar 25 11:57am ET MorphoSys AG Reports Major Stake Change Mar 22 11:57am ET MorphoSys AG Reports Major Voting Rights Change Mar 22 7:27am ET MorphoSys Set for Novartis Takeover Post-U.S. Clearance Mar 21 12:27pm ET MorphoSys AG Announces Major Voting Rights Changes Mar 20 4:57pm ET MorphoSys’ Milestone Year Paves Way for Growth Mar 20 12:27pm ET MorphoSys AG Announces Shift in Shareholding Mar 19 11:57am ET MorphoSys AG Reports Major Voting Rights Change Mar 18 12:27pm ET MorphoSys AG Witnesses Major Voting Rights Shift Mar 14 3:22pm ET MorphoSys downgraded to Equal Weight from Overweight at Wells Fargo Mar 14 11:05am ET Morphosys Ag (MOR) Receives a Hold from JMP Securities Mar 13 2:19pm ET Morphosys Ag (ADR) options imply 3.4% move in share price post-earnings Feb 15 11:45am ET Morphosys Ag (ADR) call volume above normal and directionally bullish Feb 08 11:40am ET Biotech Alert: Searches spiking for these stocks today Feb 08 4:37am ET MorphoSys downgraded to Neutral from Buy at UBS Feb 07 11:01am ET Biotech Alert: Searches spiking for these stocks today Feb 06 3:10pm ET MorphoSys downgraded to Market Perform from Outperform at JMP Securities Feb 06 1:48pm ET MorphoSys tells Bloomberg STAT story ‘factually wrong’ Feb 06 1:46pm ET JMP Securities downgrades Morphosys Ag (MOR) to a Hold Feb 06 11:52am ET Novartis will ‘walk away from’ deal to buy MorphoSys, STAT’s Feuerstein says Feb 06 5:17am ET M & A News: Novartis (NYSE:NVS) Acquires MorphoSys in $2.9B Deal Feb 06 5:14am ET MorphoSys upgraded to Neutral from Sell at Citi Feb 05 4:59pm ET Novartis to acquire MorphoSys for EUR 68 per share, or aggregate of EUR 2.7B

No recent news articles are available for MOR

No recent press releases are available for MOR

MOR Financials

1-year income & revenue

Key terms

MOR Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

MOR Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms